ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The Company is developing two novel anti-HBV compounds with complementary mechanisms of action: TXL™, a highly potent analog of the successful antiviral drug tenofovir currently in Phase 2a, which has demonstrated the potential for low, once a day dosing compared to Viread® and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. ContraVir is also developing Valnivudine™, an orally available nucleoside analogue prodrug for the treatment of herpes zoster, or shingles, in a Phase 3 clinical trial. In addition to direct antiviral activity, Valnivudine™ has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study. For more information visit www.contravir.com
View Top Employees from ContraVir Pharmaceuticals, Inc.Website | http://contravir.com |
Ticker | HEPA |
Revenue | $4 million |
Employees | 15 (6 on RocketReach) |
Founded | 2013 |
Address | 399 Thornall St, Fl 1, Edison, New Jersey 08837, US |
Phone | (732) 902-4000 |
Fax | (732) 902-4100 |
Industry | Biotechnology, Business Services General, Pharmaceuticals, Business Services, Drug Discovery, Antivirals, Executive Office, Shingles, Hepatitis B |
Web Rank | 3 Million |
Keywords | Contravir Pharmaceuticals, Ctrv, Contravir Pharmaceuticals Inc. News, Crv431, Contravir Pharmaceuticals Inc |
Competitors | Alios BioPharma, Cerecor, Inc., Eiger BioPharmaceuticals, Otonomy, Inc, Quince Therapeutics |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular ContraVir Pharmaceuticals, Inc. employee's phone or email?
The ContraVir Pharmaceuticals, Inc. annual revenue was $4 million in 2023.
Daniel Trepanier is the Director, Drug Development of ContraVir Pharmaceuticals, Inc..
6 people are employed at ContraVir Pharmaceuticals, Inc..
ContraVir Pharmaceuticals, Inc. is based in Edison, New Jersey.
The NAICS codes for ContraVir Pharmaceuticals, Inc. are [3254, 32541, 325, 32].
The SIC codes for ContraVir Pharmaceuticals, Inc. are [283, 28].